Sanofi manufacturing glitch yields insulin pen shortage

Citing a "technical incident" at a manufacturing plant in Frankfurt, Germany, Sanofi ($SNY) reports that a worldwide shortage of the Apidra Solostar insulin pen will begin this month. The incident, which involved the production of the pens but not the short-acting drug, occurred in July.

"An in-depth investigation and additional controls were immediately carried out," the company informed doctors in a letter now posted on the FDA website. "We have proactively notified" the FDA of the event.

Competing products are widely available in the U.S., Dow Jones reports.

The letter also says Sanofi expects to return to normal supply levels by the first quarter of next year. In the meantime, the company recommends that doctors consider switching patients to Apidra vials and syringes. The product currently on the market is safe, the letter says.

- here's the letter (.pdf)
- see this story

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.